MA54383A - Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique - Google Patents
Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophiqueInfo
- Publication number
- MA54383A MA54383A MA054383A MA54383A MA54383A MA 54383 A MA54383 A MA 54383A MA 054383 A MA054383 A MA 054383A MA 54383 A MA54383 A MA 54383A MA 54383 A MA54383 A MA 54383A
- Authority
- MA
- Morocco
- Prior art keywords
- neurofilamentous
- protein
- lateral sclerosis
- amyotrophic lateral
- therapeutic intervention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776253P | 2018-12-06 | 2018-12-06 | |
| US201962840431P | 2019-04-30 | 2019-04-30 | |
| US201962842063P | 2019-05-02 | 2019-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54383A true MA54383A (fr) | 2021-10-13 |
Family
ID=68966114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054383A MA54383A (fr) | 2018-12-06 | 2019-12-03 | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12429487B2 (fr) |
| EP (1) | EP3890752A1 (fr) |
| JP (2) | JP2022513721A (fr) |
| KR (1) | KR20210102294A (fr) |
| CN (1) | CN113365640A (fr) |
| BR (1) | BR112021010660A2 (fr) |
| CA (1) | CA3121749A1 (fr) |
| MA (1) | MA54383A (fr) |
| MX (1) | MX2021006548A (fr) |
| WO (1) | WO2020117772A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019211446B2 (en) | 2018-01-25 | 2025-07-03 | Biogen Ma Inc. | Methods of treating spinal muscular atrophy |
| MA54383A (fr) | 2018-12-06 | 2021-10-13 | Biogen Ma Inc | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique |
| KR102858957B1 (ko) | 2019-06-11 | 2025-09-12 | 쿨리케 & 소파 네덜란드 비.브이. | 광학 시스템 특성의 조정에 의해 개별 콤포넌트의 어셈블레에서의 위치 오차 보상 |
| WO2022091086A1 (fr) * | 2020-10-26 | 2022-05-05 | Hadasit Medical Research Services And Development Ltd. | Cellules souches mésenchymateuses et leur culture |
| KR200498472Y1 (ko) | 2024-05-23 | 2024-10-24 | 김민경 | 경고 또는 안내 문구를 교체형으로 구성시킬 수 있는 배수용 그레이팅 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
| CA2451643C (fr) | 2001-06-21 | 2012-11-13 | Isis Pharmaceuticals, Inc. | Modulation anti-sens de l'expression de la superoxyde dismutase 1 soluble |
| US8361977B2 (en) | 2005-06-23 | 2013-01-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of SMN2 splicing |
| WO2008127974A1 (fr) | 2007-04-13 | 2008-10-23 | The Trustees Of Columbia University In The City Of New York | Système de culture à base de cellules souches pour la mise au point de médicaments |
| SG10202109219SA (en) | 2009-05-02 | 2021-10-28 | Genzyme Corp | Gene therapy for neurodegenerative disorders |
| PT3449926T (pt) | 2009-06-17 | 2019-11-12 | Cold Spring Harbor Laboratory | Composições e métodos de modulação de excisões de smn2 em um sujeito |
| US8465727B2 (en) | 2009-10-06 | 2013-06-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biomarkers for the diagnosis of ALS |
| SMT202000347T1 (it) | 2012-05-09 | 2020-07-08 | Biogen Ma Inc | Modulatori di trasporto nucleare e loro usi |
| WO2014062736A1 (fr) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Procédés permettant de surveiller l'expression de c9orf72 |
| ES2762326T5 (es) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
| US10443052B2 (en) | 2012-10-15 | 2019-10-15 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
| CA2889499C (fr) | 2012-10-24 | 2019-09-10 | Daiichi Sankyo Company, Limited | Agonistes du recepteur des secretagogues d'hormone de croissance servant au traitement de la sclerose laterale amyotrophique |
| WO2014110291A1 (fr) | 2013-01-09 | 2014-07-17 | Isis Pharmaceuticals, Inc. | Compositions et procédés pour la modulation de l'épissage de smn2 chez un sujet |
| MX2016004651A (es) | 2013-10-11 | 2016-08-05 | Ionis Pharmaceuticals Inc | Composiciones para modular la expresion de c9orf72. |
| WO2015057727A1 (fr) | 2013-10-14 | 2015-04-23 | Isis Pharmaceuticals, Inc. | Compositions destinées à moduler l'expression du transcrit antisens c9orf72 |
| AU2014337506B2 (en) | 2013-10-14 | 2020-10-15 | Ionis Pharmaceuticals, Inc. | Methods for modulating expression of C9ORF72 antisense transcript |
| EP3119888B1 (fr) | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Compositions permettant de moduler l'expression de l'ataxine 2 |
| US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
| SI3757214T1 (sl) | 2014-04-01 | 2022-08-31 | Biogen Ma Inc. | Sestave za moduliranje izražanja SOD-1 |
| US10024870B2 (en) | 2014-04-02 | 2018-07-17 | Wisconsin Alumni Research Foundation | Therapeutic and diagnostic methods and compositions for neurodegenerative diseases |
| MA39835A (fr) | 2014-04-17 | 2017-02-22 | Biogen Ma Inc | Compositions et procédés de modulation de l'épissage du smn2 chez un patient |
| US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
| AU2015326911C1 (en) | 2014-09-30 | 2025-12-18 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (DPRs) antibody |
| RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
| US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
| EP3722424A1 (fr) | 2015-04-16 | 2020-10-14 | Ionis Pharmaceuticals, Inc. | Compositions pour moduler l'expression de c9orf72 |
| WO2016167780A1 (fr) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions destinées à moduler l'expression du transcrit antisens c9orf72 |
| WO2017079291A1 (fr) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Composés et méthodes de modulation de c90rf72 |
| WO2017117496A1 (fr) | 2015-12-31 | 2017-07-06 | Ionis Pharmaceuticals, Inc. | Méthodes pour diminuer l'expression de l'ataxine-2 |
| US20190142856A1 (en) | 2016-04-13 | 2019-05-16 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
| US20210172963A1 (en) | 2017-05-26 | 2021-06-10 | University Of Miami | Determining onset of amyotrophic lateral sclerosis |
| CA3072076A1 (fr) | 2017-08-08 | 2019-02-14 | Wave Life Sciences Ltd. | Compositions oligonucleotidiques et methodes associees |
| CN111479924B (zh) | 2017-10-16 | 2024-06-14 | 沃雅戈治疗公司 | 肌萎缩性侧索硬化症(als)的治疗 |
| AU2019211446B2 (en) | 2018-01-25 | 2025-07-03 | Biogen Ma Inc. | Methods of treating spinal muscular atrophy |
| EA201992364A1 (ru) | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
| CA3097872A1 (fr) | 2018-04-27 | 2019-10-31 | Biogen Ma Inc. | Anticorps anti-(poly-ga) dirige contre des repetitions dipeptidiques (dpr) d'origine humaine |
| WO2020061355A2 (fr) | 2018-09-20 | 2020-03-26 | Biogen Ma Inc. | Protéine neurofilamenteuse sérique pour guider une intervention thérapeutique dans la sclérose en plaques |
| MA54383A (fr) | 2018-12-06 | 2021-10-13 | Biogen Ma Inc | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique |
| TWI906204B (zh) | 2018-12-14 | 2025-12-01 | 美商百健Ma公司 | 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 |
| MA54949A (fr) | 2019-02-12 | 2021-12-22 | Biogen Ma Inc | Biomarqueurs de la leucoencéphalopathie multifocale progressive |
-
2019
- 2019-12-03 MA MA054383A patent/MA54383A/fr unknown
- 2019-12-03 EP EP19824179.6A patent/EP3890752A1/fr active Pending
- 2019-12-03 BR BR112021010660-0A patent/BR112021010660A2/pt unknown
- 2019-12-03 CN CN201980080522.8A patent/CN113365640A/zh active Pending
- 2019-12-03 MX MX2021006548A patent/MX2021006548A/es unknown
- 2019-12-03 JP JP2021531983A patent/JP2022513721A/ja not_active Withdrawn
- 2019-12-03 KR KR1020217020744A patent/KR20210102294A/ko active Pending
- 2019-12-03 CA CA3121749A patent/CA3121749A1/fr active Pending
- 2019-12-03 WO PCT/US2019/064190 patent/WO2020117772A1/fr not_active Ceased
- 2019-12-03 US US17/299,660 patent/US12429487B2/en active Active
-
2024
- 2024-04-26 JP JP2024072811A patent/JP2024096258A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113365640A (zh) | 2021-09-07 |
| US12429487B2 (en) | 2025-09-30 |
| JP2022513721A (ja) | 2022-02-09 |
| CA3121749A1 (fr) | 2020-06-11 |
| KR20210102294A (ko) | 2021-08-19 |
| MX2021006548A (es) | 2021-09-21 |
| JP2024096258A (ja) | 2024-07-12 |
| US20220034907A1 (en) | 2022-02-03 |
| WO2020117772A1 (fr) | 2020-06-11 |
| EP3890752A1 (fr) | 2021-10-13 |
| BR112021010660A2 (pt) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54383A (fr) | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique | |
| EP3773729A4 (fr) | Molécules bi-fonctionnelles pour dégrader des protéines circulantes | |
| EP3765032A4 (fr) | Exosomes suppresseurs dans le cancer et pour l'immunosuppression | |
| EP3710008A4 (fr) | Inhibition de runx1 pour le traitement de la vitréorétinopathie proliférative et d'états associés à une transition épithéliale à mésenchymateuse | |
| EP3341413A4 (fr) | Traitement ciblé par anticorps monoclonal anti-despr et imagerie pour cancer et avc | |
| EP2953964A4 (fr) | Procédés pour réduire les niveaux d'agrégats dans les préparations protéiniques par traitement par des cations thiohétérocycliques | |
| EP3307371A4 (fr) | Cathéter avec géométrie pré-formée pour l'accès à une lumière corporelle. | |
| EP3004329A4 (fr) | Procédé d'induction d'une apoptose partielle au moyen de polypeptides de caspase | |
| EP3326028A4 (fr) | Réglage de phase dans des groupes de guides d'ondes | |
| EP3746103A4 (fr) | Protéines modifiées pour améliorer la sensibilité d'une cellule à l'il-2 | |
| EP3308783A4 (fr) | Utilisation d'une composition pour la fabrication d'un médicament dans le traitement de la sclérose latérale amyotrophique | |
| EP3640335A4 (fr) | Plateforme pour exprimer une protéine d'intérêt dans le foie | |
| EP3781184A4 (fr) | Interventions thérapeutiques recombinantes pour le cancer | |
| EP2968482A4 (fr) | Arginine désiminase à réactivité croisée réduite envers les anticorps anti-adi-peg 20 pour le traitement du cancer | |
| EP3362637A4 (fr) | Ensemble d'ancrage hydraulique pour pompe insérable à cavité évolutive | |
| MA52801A (fr) | Conjugués oligomères à saut d'exon pour dystrophie musculaire | |
| EP3794151A4 (fr) | Souches modifiées sec pour sécrétion améliorée de protéines recombinantes | |
| EP3847365A4 (fr) | Moteur pour produire une poussée | |
| EP3408413A4 (fr) | Prédiction d'une réponse thérapeutique dans des états inflammatoires | |
| EP3866804A4 (fr) | Combinaisons pour modulation immunitaire dans le traitement du cancer | |
| FR3043925B1 (fr) | Formage d'un coude dans une ondulation | |
| EP2849781A4 (fr) | Traitement de céphalées migraineuses à l'aide d'une neurotoxine présynaptique | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| EP2950633A4 (fr) | Procédés pour induire une tolérance à la sécheresse dans des cultures | |
| EP3508202A4 (fr) | Agent thérapeutique pour la sclérose latérale amyotrophique et composition pour traitement |